Allergy immunotherapy: What is the evidence for cost saving?

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 4, 2014, Pages 363-370

  Hankin, Cheryl S ^a   Cox, Linda ^b  

^a BioMedEcon LLC   (United States)

^b Allergy and Asthma Center   (United States)

Author keywords

allergy immunology; cost analyses; health economics; systematic literature review

Indexed keywords

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ASTHMA; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; GRASS POLLEN; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOUSE DUST ALLERGY; HUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; REVIEW; RHINOCONJUNCTIVITIS; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ECONOMICS; HYPERSENSITIVITY; PROCEDURES; STANDARDS;

COST SAVINGS; HUMANS; HYPERSENSITIVITY; SUBLINGUAL IMMUNOTHERAPY;

EID: 84903786602     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000084     Document Type: Review

References (67)

1. Schoenwetter WF. Allergic rhinitis: epidemiology and natural history. Allergy Asthma Proc 2000; 21:1-6.
2. Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis 2012; 6:11-23.
3. Valovirta E, editor. EFA book on respiratory allergies. Brussels, Belgium: European Federation of Allergy and Airways Diseases Patients Associations; 2011. Available at http://www.theipcrg.org/download/attachments/ 689587/ EFABookonRespiratoryAllergiesFINAL.pdf?version=1&modificationDate= 1332965739000. [Accessed 6th May 2014]
4. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008; 122 (2 Suppl.):S1-S84.
5. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127 (1 Suppl.):S1-S55.
6. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PATstudy). J Allergy Clin Immunol 2002; 109:251-256.
7. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114:851-857.
8. Polosa R, Li Gotti F, Mangano G, et al. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy 2004; 59:1224-1228.
9. Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-termprevention of asthma in children. Allergy 2006; 61:855-859.
10. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year followup on the PAT study. Allergy 2007; 62:943-948.
11. Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008; 101:206-211.
12. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99:450-453.
13. Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-1397.
14. Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not: a retrospective study. Clin Exp Allergy 2001; 31:1295-1302.
15. Marogna M, Falagiani P, Bruno M, et al. The allergic march in pollinosis: natural history and therapeutic implications. Int Arch Allergy Immunol 2004; 135:336-342.
16. Gulen F, Zeyrek D, Can D, et al. Development of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. Asian Pac J Allergy Immunol 2007; 25:7-11.
17. Inal A, Altintas DU, Yilmaz M, et al. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol 2007; 17:85-91.
18. Reha CM, Ebru A. Specific immunotherapy is effective in the prevention of new sensitivities. Allergol Immunopathol (Madr) 2007; 35:44-51.
19. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010; 126:969-975.
20. Hedlin G, Heilborn H, Lilja G, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995; 96 (6 Pt 1):879-885.
21. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grasspollen immunotherapy. N Engl J Med 1999; 341:468-475.
22. Grammer LC, Shaughnessy MA, Suszko IM, et al. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Immunol 1984; 73:484-489.
23. Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988; 43:523-529.
24. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51:430-433.
25. Musarra A, Bignardi D, Troise C, Passalacqua G. Long-lasting effect of a monophosphoryl lipid-adjuvanted immunotherapy to parietaria: a controlled field study. Eur Ann Allergy Clin Immunol 2010; 42:115-119.
26. James LK, Shamji MH, Walker SM, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011; 127:509-516; e501-e505.
27. Tabar AI, Arroabarren E, Echechipia S, et al. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011; 127:47-63.
28. Ariano R, Kroon AM, Augeri G, et al. Long-term treatment with allergoid immunotherapy with Parietaria: clinical and immunologic effects in a randomized, controlled trial. Allergy 1999; 54:313-319.
29. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006; 61:198-201.
30. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002; 57:306-312.
31. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003; 33:206-210.
32. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125:131-138; e131-e137.
33. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129:717-725; e715.
34. Tahamiler R, Saritzali G, Canakcioglu S. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope 2007; 117:965-969.
35. Didier A, Malling HJ, Worm M, et al. Posttreatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin. Exp Allergy 2013; 43:568-577.
36. Marogna M, Bruno M, Massolo A, Falagiani P. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: a long-term (13-year) retrospective study in real life. Int Arch Allergy Immunol 2007; 142:70-78.
37. Stallergenes. Oralair [Product Insert]. Antony, France: Stallergenes S.A.; 2014.
38. Merck. Grastek [Product Insert]. Whitehouse Station, NJ: Merck & Co.; 2014.
39. Merck. Ragwitek [Product Insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2014.
40. Ariano R, Berto P, Tracci D, et al. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 2006; 27:159-163.
41. Bruggenjurgen B, Reinhold T, Brehler R, et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol 2008; 101:316-324.
42. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996; 334:501-506.
43. Donahue JG, Greineder DK, Connor-Lacke L, et al. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol 1999; 82:339-347.
44. Hankin CS, Cox L, Lang D, et al. Allergy immunotherapy among Medicaidenrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol 2008; 121:227-232.
45. Hankin CS, Cox L, Lang D, et al. Allergen immunotherapy and healthcare cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol 2010; 104:79-85.
46. Hankin CS, Cox L, Bronstone A, Wang Z. Allergy immunotherapy: reduced healthcare costs in adults and children with allergic rhinitis. J Allergy Clin Immunol 2013; 131:1084-1091.
47. Keiding H, Jorgensen KP. A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries. Curr Med Res Opin 2007; 23:1113-1120.
48. Mauro M, Russello M, Alesina R, et al. Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. Eur Ann Allergy Clin Immunol 2006; 38:31-34.
49. Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr) 2005; 33:296-302.
50. Reinhold M, Willich S, Brüggenjürgen B. Subcutaneous specific immunotherapy: economic implications from the perspective of statutory health insurance - a population based cost-effectiveness estimation. Allergologie 2012; 35:539-550.
51. Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000; 17:37-52.
52. Bachert C, Vestenbaek U, Christensen J, et al. Cost-effectiveness of grass allergen tablet (GRAZAX(R)) for the prevention of seasonal grass pollen induced rhinoconjunctivitis: a Northern European perspective. Clin Exp Allergy 2007; 37:772-779.
53. Beriot-Mathiot A, Vestenbaek U, Bo Poulsen P. Influence of time horizon and treatment patterns on cost-effectiveness measures: the case of allergen-specific immunotherapy with Grazax. J Med Econ 2007; 10: 215-228.
54. Berto P, Bassi M, Incorvaia C, et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Allerg Immunol (Paris) 2005; 37:303-308.
55. Berto P, Passalacqua G, Crimi N, et al. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol 2006; 97:615-621.
56. Berto P, Frati F, Incorvaia C, et al. Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study. Curr Med Res Opin 2008; 24:261-266.
57. Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62 (Suppl. 85):17-25.
58. Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 2008; 63:1624-1629.
59. Ruggeri M, Oradei M, Frati F, et al. Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic rhinitis in adults. Clin Drug Investig 2013; 33:343-349.
60. Ariano R, Berto P, Incorvaia C, et al. Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma. Ann Allergy Asthma Immunol 2009; 103:254-259.
61. Seiberling K, Hiebert J, Nyirady J, et al. Cost of allergy immunotherapy: sublingual vs subcutaneous administration. Int Forum Allergy Rhinol 2012; 2:460-464.
62. Dranitsaris G, Ellis AK. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost. J Eval Clin Pract 2014; 20:225-238.
63. Omnes LF, Bousquet J, Scheinmann P, et al. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. Allerg Immunol (Paris) 2007; 39:148-156.
64. Pokladnikova J, Krcmova I, Vlcek J. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 2008; 100:482-489.
65. Westerhout KY, Verheggen BG, Schreder CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J Med Econ 2012; 15:906-917.
66. Ronborg SM, Svendsen UG, Micheelsen JS, et al. Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis. Clinicoecon Outcomes Res 2012; 4:253-260.
67. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:319-325.